None listed
Conditions
Brief summary
Dexmedetomidine is a sedation medication used daily in our ICU. Though the manufacturer and literature recommends a lower dose for patient above 65 years old, the dose is yet not known. We aim to find out the best dose to be used in patients 65 years and above in our ICU, and to recommend the dose for similar patients in the whole country.
Interventions
Eligible patients will be administered 0.2 to 0.5 mcg/kg/hr intravenous dexmedetomidine to achieve RASS score of 0 to -2. Pharmacodynamic parameters monitored are the RASS score, heart rate, blood pressure, respiratory rate, temperature. Sparse blood samples will be taken to measure serum dexmedetomidine levels, where the population pharmacokinetics will be studied.
The pharmacodynamic parameters will be continuous for 48 hours, and the blood sampling will occur six times over 48 hours.
Sponsors
Noorjahan Haneem binti Md Hashim
Study design
Allocation
Non-randomised trial
Intervention model
Single group
Primary purpose
Treatment
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
65 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Intensive Care Unit (ICU) patients at the University of Malaya Medical Centre (UMMC) requiring invasive ventilation and sedation of at least 48 hours duration
Exclusion criteria
1. Patient or relative refusal 2. Previous adverse reaction to alpha2 agonists 3. Second degree or higher heart blocks 4. Liver failure 5. Kidney failure requiring renal replacement therapy
Outcome results
None listed